: Kyprolis. ?  »
|
-

I.V

Powder For Solution For Injection

Kyprolis is a proteasome inhibitor indicated to the treatment of patients with multiple myeloma who have received at least 2 prior therapies including bortezomib and an immunomoludatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate. Clinical benefit , such as improvement in survival or symptoms , has not been verified.

151 21 33948 00

Amgen Europe B.v., Netherlands

01/2014 - 12/2018

.
, .
.
/
Carfilzomib 60 MG/VIAL
Vial 50 ml glass type i 1 x VIAL 36

*

*

 

.

 
" !
 
278
,